Nonalcoholic fatty liver disease patients with type 2 diabetes
Conditions
Interventions
Dapagliflozin 5mg Sig. 1 or 2 tab po once time a day
Pioglitazone 15mg Sig. 1 or 2 tab po once time a day
Glimepiride 0.5 or 1mg Sig. 1 or 3 tab po once or two times a day
Sponsors
Kawasaki Medical SchoolKawasaki Medical School Devision of Diabetes, Endocrinology and Metabolism
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Nonalcoholic fatty liver disease patients with type 2 diabetes mellitus who visit a hospital for treatment in the outpatient department of the facilities concerned.
Exclusion criteria
Exclusion criteria: A) Under 20 years old B) Treatment with insulin C) Treatment with SGLT-2 inhibitor, thiazolidinedione or sulfonylurea D) Diabetic coma E) Renal dysfunction (eGFR<45mL/min) F) Cardiac failure G) Viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, liver cirrhosis H) Infection I) During treatment or treatment plan of malignant neoplasm J) Autoimmune disease K) Use of Steroid medicine and/or immunosuppressor L) Pregnant, possibility of pregnancy, nursing or hope to become pregnant during the study period M) In addition, when principal investigator or researcher deems inappropriate as a study subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of liver function and L/S ratio (CT) six months after the intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of body weight, visceral fat amount, fasting plasma glucose (FPG), insulin, triacylglycerol (TG), non-esterified fatty acid (NEFA), HDL-cholesterol, LDL-cholesterol, lipoprotein fractionation, adiponectin, hsCPR, TNF-alpha, MCP-, MDA, typIV collagen7S, P-III-P, M2BP, the fibrosis score (NAFLD fibrosis score, FIB-4 index, APRI, BARD score, BAAT score), proinsulin/S-CPR ratio | — |
Countries
Japan
Contacts
Public ContactMasashi Shimoda
Kawasaki Medical SchoolKawasaki Medical School Devision of Diabetes, Endocrinology and Metabolism
Outcome results
None listed